Antibody-Targeted Imaging of Gastric Cancer.
Komal MandleywalaShayla ShmuelPatricia M R PereiraJason S LewisPublished in: Molecules (Basel, Switzerland) (2020)
The specificity of antibodies for antigens overexpressed or uniquely expressed in tumor cells makes them ideal candidates in the development of bioconjugates for tumor imaging. Molecular imaging can aid clinicians in the diagnosis of gastric tumors and in selecting patients for therapies targeting receptors with a heterogeneous intratumoral or intertumoral expression. Antibodies labeled with an imaging radiometal can be used to detect primary tumors and metastases using whole-body positron emission tomography (PET) or single photon emission computed tomography (SPECT), both during diagnosis and monitoring disease response. Conjugated with fluorescent dyes, antibodies can image tumors by targeted optical imaging. This review provides an overview of the most recent advances in the use of antibodies labeled with radiometals or conjugated with fluorescent dyes for gastric cancer imaging.
Keyphrases
- computed tomography
- positron emission tomography
- high resolution
- pet imaging
- pet ct
- magnetic resonance imaging
- cancer therapy
- quantum dots
- newly diagnosed
- photodynamic therapy
- end stage renal disease
- poor prognosis
- ejection fraction
- magnetic resonance
- deep learning
- dendritic cells
- prognostic factors
- chronic kidney disease
- living cells
- fluorescence imaging
- high speed
- patient reported